# Introduction to Autonomic Pharmacology

Yacoub Irshaid MD, PhD, ABCP Department of Pharmacology

## Introduction to Autonomic Pharmacology

- The autonomic nervous system activities are NOT under direct conscious control.
- It is concerned primarily with visceral functions such as cardiac output, blood flow and digestion, ...etc .

## **Autonomic Nervous System**


It consists of 2 major divisions:

- **1.** Sympathetic (thoracolumbar)
- 2. Parasympathetic (craniosacral)
- Both divisions originate in nuclei within the central nervous system, giving rise to preganglionic efferent fibers that exit from brain stem or spinal cord and terminate in autonomic ganglia.

## **Autonomic Nervous System**

• From the autonomic ganglia, postganglionic fibers run to the tissues involved.

#### **Autonomic Nervous System**



Preganglionic nerve Postganglionic nerve

- Neurons of the ANS release neurotransmitters into the synapse, which carry information to/or activate the next cells.
- These chemicals may be:
- 1. Acetylcholine and the nerves that release it are called cholinergic.
- 2. Norepinephrine (noradrenaline) and the nerves that release it are called adrenergic.




FIGURE 6–1 Schematic diagram comparing some anatomic and neurotransmitter features of autonomic and somatic motor nerves. Only the primary transmitter substances are shown. Parasympathetic ganglia are not shown because most are in or near the wall of the organ innervated. Cholinergic nerves are shown in blue, noradrenergic in red. Note that some sympathetic postganglionic fibers release acetylcholine rather than norepinephrine. Sympathetic nerves to the renal vasculature and kidney may release dopamine as well as norepinephrine during stress. The adrenal medulla, a modified sympathetic ganglion, receives sympathetic preganglionic fibers and releases epinephrine and norepinephrine into the blood. ACh, acetylcholine; D, dopamine; Epi, epinephrine; M, muscarinic receptors; N, nicotinic receptors; NE, norepinephrine.

**Cholinergic fibers include:** 


- 1. All autonomic preganglionic fibers.
- 2. Most parasympathetic postganglionic fibers.
- 3. Few sympathetic postganglionic fibers (sweat gland).

**Adrenergic fibers include:** 

- 1. Most sympathetic postganglionic fibers.
- 2. Some sympathetic postganglionic fiber release dopamine.
- 3. Adrenal medulla releases a mixture of epinephrine and norepinephrine.
- Most autonomic nerves also release cotransmitters in addition.

Key features of neurotransmitters as potential targets for pharmacologic agents:

- 1. Synthesis.
- 2. Storage.
- 3. Release.
- 4. Termination of action.
- 5. Act on receptors.



## FIGURE 6–3 Schematic ilustration of a generalized cholinergic junction (not to scale).

Choline is transported into the presynaptic nerve terminal by a sodiumdependent choline transporter (CHT). This transporter can be inhibited by hemicholinium drugs. In the cytoplasm, acetylcholine is synthesized from choline and acetyl-CoA (AcCoA) by the enzyme choline acetyltransferase (ChAT). Acetylcholine (ACh) is then transported into the storage vesicle by a vesicle-associated transporter (VAT), which can be inhibited by vesamicol. Peptides (P), adenosine triphosphate (ATP), and proteoglycan are also stored in the vesicle. Release of transmitters occurs when voltage-sensitive calcium channels in the terminal membrane are opened, a lowing an influx of calcium. The resulting increase in intracelular calcium causes fusion of vesicles with the surface membrane and exocytotic expulsion of acetylcholine and cotransmitters into the junctional cleft (see text). This step can be blocked by botulinum toxin. Acetylcholine's action is terminated by metabolism by the enzyme acetylcholinesterase. Receptors on the presynaptic nerve ending modulate transmitter release.

SNAPs, synaptosomal nerve associated proteins; VAMPs, vesicle-associated membrane proteins.





FIGURE 6–4 Schematic diagram of a generalized noradrenergic junction (not to scale).

Tyrosine is transported into the noradrenergic ending or varicosity by a sodium-dependent carrier (A). Tyrosine is converted to dopamine (see Figure 6–5 for details), and transported into the vesicle by the vesicular monoamine transporter (VMAT), which can be blocked by reserpine. The same carrier transports norepinephrine (NE) and several related amines into these vesicles. Dopamine is converted to NE in the vesicle by dopamine- $\beta$ hydroxylase. Physiologic release of transmitter occurs when an action potential opens voltage-sensitive calcium channels and increases intracellular calcium. Fusion of vesicles with the surface membrane results in expulsion of norepinephrine, cotransmitters, and dopamine  $\beta$ -hydroxylase. Release can be blocked by drugs such as guanethidine and bretylium. After release, norepinephrine diffuses out of the cleft or is transported into the cytoplasm of the terminal by the norepinephrine transporter (NET), which can be blocked by cocaine and certain antidepressants, or into postjunctional or perijunctional cells. Regulatory receptors are present on the presynaptic terminal.


SNAPs, synaptosome-associated proteins; VAMPs, vesicle-associated membrane proteins.



#### FIGURE 6–5 Biosynthesis of catecholamines.

The rate-limiting step, conversion of tyrosine to dopa, can be inhibited by metyrosine ( $\alpha$  methyltyrosine). The alternative pathway shown by the dashed arrows has not been found to be of physiologic significance in humans. However, tyramine and octopamine may accumulate in patients treated with monoamine oxidase inhibitors.

(Reproduced, with permission, from Gardner DG, Shoback D [editors]: Greenspan's Basic & Clinical Endocrinology, 9th ed. McGraw-Hil, 2011. Copyright © The McGraw-Hil Companies, Inc.)



IGURE 6-6 Metabolism of catecholamines by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). (Reproduced,

#### **Autonomic Receptors**

- Cholinoceptors (Cholinergic): Receptors stimulated by acetylcholine. Muscarinic and nicotinic receptors stimulated by the alkaloids muscarine and nicotine, respectively.
- Adrenoceptors (Adrenergic): Receptors stimulated by catecholamines such as norepinephrine (noradrenaline).
- Dopamine receptors (Dopaminergic): Receptors stimulated by dopamine.

#### **Autonomic Receptors**

#### TABLE 6-2 Major autonomic receptor types.

Receptor Name	Typical Locations	Result of Ligand Binding	
Cholinoceptors			
Muscarinic M <sub>1</sub>	CNS neurons, sympathetic postganglionic neurons, some presynaptic sites	Formation of IP <sub>3</sub> and DAG, increased intracellular calcium	
Muscarinic $M_2$	Myocardium, smooth muscle, some presynaptic sites; CNS neurons	Opening of potassium channels, inhibition of adenylyl cyclase	
$Muscarinic M_3$	Exocrine glands, vessels (smooth muscle and endothelium); CNS neurons	Like M1 receptor-ligand binding	
Muscarinic M <sub>4</sub>	CNS neurons; possibly vagal nerve endings	Like M <sub>2</sub> receptor-ligand binding	
$Muscarinic M_5$	Vascular endothelium, especially cerebral vessels; CNS neurons	Like M1 receptor-ligand binding	
Nicotinic N <sub>N</sub>	Postganglionic neurons, some presynaptic cholinergic terminals; receptors typically contain two $\alpha 3$ and one $\beta 4$ type subunits in addition to $\gamma$ and $\delta$ subunits	Opening of Na $^{\!\!+}, \mathrm{K}^{\!\!+}$ channels, depolarization	
Nicotinic N <sub>M</sub>	Skeletal muscle neuromuscular end plates; receptors typically contain two $\alpha 1$ and $\beta 1$ type subunits in addition to $\gamma$ and $\delta$ subunits	Opening of Na $^{\scriptscriptstyle +}, {\rm K}^{\scriptscriptstyle +}$ channels, depolarization	

## **Autonomic Receptors**

Adrenoceptors							
Alpha <sub>1</sub>	Postsynaptic effector cells, especially smooth muscle	Formation of $IP_3$ and DAG, increased intracellular calcium					
Alpha <sub>2</sub>	Presynaptic adrenergic nerve terminals, platelets, lipocytes, smooth muscle	mooth muscle Inhibition of adenylyl cyclase, decreased cAMP					
Beta <sub>1</sub>	Postsynaptic effector cells, especially heart, lipocytes, brain; presynaptic adrenergic and cholinergic nerve terminals, juxtaglomerular apparatus of renal tubules, ciliary body epithelium	Stimulation of adenylyl cyclase, increased cAMP					
Beta <sub>2</sub>	Postsynaptic effector cells, especially smooth muscle and cardiac muscle	Stimulation of adenylyl cyclase and increased cAMP. Activates cardiac G <sub>i</sub> under some conditions.					
Beta <sub>3</sub>	Postsynaptic effector cells, especially lipocytes; heart	Stimulation of adenylyl cyclase and increased cAMP <sup>1</sup>					
Dopamine receptors							
D1 (DA1), D5	Brain; effector tissues, especially smooth muscle of the renal vascular bed	Stimulation of adenylyl cyclase and increased cAMP					
D <sub>2</sub> (DA <sub>2</sub> )	Brain; effector tissues, especially smooth muscle; presynaptic nerve terminals	Inhibition of adenylyl cyclase; increased potassium conductance					
D <sub>3</sub>	Brain	Inhibition of adenylyl cyclase					
$D_4$	Brain, cardiovascular system	Inhibition of adenylyl cyclase					

<sup>1</sup>Cardiac β<sub>3</sub>-receptor function is poorly understood, but activation does not appear to result in stimulation of rate or force.

- Negative feedback control is found at the presynaptic level of autonomic function, such as:
- Presynaptic α<sub>2</sub>-adrenoceptors when activated by norepinephrine and similar substances lead to reduction of further norepinephrine release.

- Conversely, Presynaptic β-adrenoceptors when activated by norepinephrine and similar substances facilitate further norepinephrine release.
- These receptors are called autoreceptors.
- Heteroreceptors may also be involved in presynaptic regulation. They are activated by substances released from other nerve terminals.

- 1. Some vagal fibers in the myocardium synapse on sympathetic noradrenergic nerve terminals and inhibit norepinephrine release.
- 2. Alternatively, some substances move to these receptors from the blood or nearby tissues.

- 3. Serotonin (5-HT) stimulation of its receptors at cholinergic preganglionic sites inhibits cholinergic transmission.
- 4. Adenosine and ATP stimulation of their receptors (P<sub>1</sub> and P<sub>2</sub> respectively) at adrenergic autonomic neurons inhibit adrenergic function.
- Angiotensin II stimulates its receptor (AT<sub>2</sub>-1) at adrenergic nerve terminals & stimulates adrenergic transmission.

#### **Postsynaptic regulation**

- 1. Up-regulation of receptors: Increased number of receptors upon continued decreased receptor activation by antagonist.
- 2. Down regulation of receptors: Decreased number of receptors upon continued increased receptor activation by agonist.

#### **Effects of Autonomic Nerve Activation**

TABLE 6-3 Direct effects of autonomic *nerve* activity on some organ systems. Autonomic *drug* effects are similar but not identical (see text).

	Effect of				
	Sympathetic Activity		Parasympatheti	Parasympathetic Activity	
Organ	Action <sup>1</sup>	Receptor <sup>2</sup>	Action	Receptor <sup>2</sup>	
Eye					
Iris radial muscle	Contracts	α,			
Iris circular muscle			Contracts	M <sub>3</sub>	
Ciliary muscle	[Relaxes]	β	Contracts	M <sub>3</sub>	
Heart					
Sinoatrial node	Accelerates	$\beta_1, \beta_2$	Decelerates	M <sub>2</sub>	
Ectopic pacemakers	Accelerates	$\beta_1, \beta_2$			
Contractility	Increases	$\beta_1, \beta_2$	Decreases (atria)	M <sub>2</sub>	
Blood vessels					
Skin, splanchnic vessels	Contracts	α			
Skeletal muscle vessels	Relaxes	β2			
	[Contracts]	α			
	Relaxes <sup>3</sup>	M <sub>3</sub>			
Endothelium of vessels in heart, brain, viscera			Synthesizes and releases EDRF <sup>4</sup>	M <sub>3</sub> , M <sub>5</sub> <sup>5</sup>	
Bronchiolar smooth muscle	Relaxes	$\beta_2$	Contracts	M <sub>3</sub>	

## **Effects of Autonomic Nerve Activation**

Genitourinary smooth muscle								
Bladder wall	Relaxes	β <sub>2</sub>	Contracts	M <sub>3</sub>				
Sphincter	Contracts	α,	Relaxes	M <sub>3</sub>				
Uterus, pregnant	Relaxes	β <sub>2</sub>						
	Contracts	α	Contracts	M <sub>3</sub>				
Penis, seminal vesicles	Ejaculation	α	Erection	M				
Skin								
Pilomotor smooth muscle	Contracts	α						
Sweat glands								
Eccrine	Increases	М						
Apocrine (stress)	Increases	α						
Metabolic functions								
Liver	Gluconeogenesis	β2, α						
Liver	Glycogenolysis	β <sub>2</sub> , α						
Fat cells	Lipolysis	$\beta_3$						
Kidney	Renin release	$\beta_1$						

<sup>1</sup>Less important actions are shown in brackets.

<sup>2</sup>Specific receptor type: α, alpha; β, beta; M, muscarinic.

<sup>3</sup>Vascular smooth muscle in skeletal muscle has sympathetic cholinergic dilator fibers.

<sup>4</sup>The endothelium of most blood vessels releases EDRF (endothelium-derived relaxing factor), which causes marked vasodilation, in response to muscarinic stimuli. Parasympathetic fibers innervate muscarinic receptors in vessels in the viscera and brain, and sympathetic cholinergic fibers innervate skeletal muscle blood vessels. The muscarinic receptors in the other vessels of the peripheral circulation are not innervated and respond only to circulating muscarinic agonists.

<sup>5</sup>Cerebral blood vessels dilate in response to M<sub>5</sub> receptor activation.

<sup>6</sup>Probably through presynaptic inhibition of parasympathetic activity.